On March 2, 2026 MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, reported the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on March 4, 2026, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering was structured as a straightforward common stock only investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.

Konik Capital Partners, LLC, a division of T.R. Winston & Company is acting as the sole book-running manager for the offering.

MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes.

The securities described above are being offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-273984), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 15, 2023, and declared effective on August 23, 2023.

The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at View Source or by contacting Konik Capital Partners LLC, a division of T.R. Winston & Company, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, MAIA Biotechnology, MAR 2, 2026, View Source [SID1234663198])

On March 2, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported on the announcement by Shanghai Henlius Biotech, Inc. that the first patient has been dosed in a Phase 2/3 clinical trial of HLX22 in combination with HLX87 (an antibody-drug conjugate targeting HER2) as a first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer. The trial (NCT07294508) is conducted in Mainland China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HLX22 is an innovative anti-HER2 monoclonal antibody that has been granted orphan drug designation in both the U.S. and EU for gastric cancer and is being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues.

"We are encouraged that Henlius continues to advance the development of HLX22 on a broad front across multiple indications," said Søren Bregenholt, CEO of Alligator Bioscience. "Conducting several clinical trials in parallel, including this Phase 2/3 study in breast cancer, demonstrates a clear strategic commitment and strong confidence in the molecule’s clinical and commercial potential. This further reinforces our view of the program’s long-term value."
Under the terms of Alligator’s agreement with AbClon, Alligator is entitled to 35% of AbClon’s revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues, which, if HLX22 is successfully developed and approved, could represent a meaningful long-term revenue opportunity for Alligator.

(Press release, Alligator Bioscience, MAR 2, 2026, View Source [SID1234663167])

On March 2, 2026 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported that members from the Replimune management team will present and host investor meetings at the following two conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leerink Partners 2026 Global Healthcare Conference
Date: Monday, March 9, 2026
Fireside Chat Time: 2:20 pm EDT

Jefferies 2026 Biotech on the Beach Summit
Date: Tuesday, March 10, 2026
1×1 Meetings

Live webcasts of the fireside chat will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.

(Press release, Replimune, MAR 2, 2026, View Source [SID1234663183])

On March 2, 2026 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), reported a targeted realignment of its R&D portfolio to reinforce execution of its previously announced 2026-2028 strategic plan. The Company will pause development of OSE‑230, allowing OSE to focus its resources on late‑stage, high‑potential assets lusvertikimab (OSE‑127) and Tedopi. These two assets are expected to generate multiple clinical catalysts over the next three years.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the same time, Boehringer Ingelheim has decided to discontinue BI 770371 in MASH following completion of an exploratory Phase 2 study that did not demonstrate efficacy in this indication. The treatment was well tolerated with a manageable safety profile, and this indication‑specific decision does not affect the molecule’s ongoing oncology development, where multiple Phase 1 studies continue as planned.

Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, commented: "These decisions mark a disciplined evolution of our portfolio. By stepping away from selected early‑stage programs which were not expected to generate meaningful value inflection points over our three-year strategic program, we are concentrating our resources where OSE can create the greatest value in the near term. This strengthened focus enhances our ability to deliver late‑stage clinical progress, secure meaningful partnerships, and accelerate Tedopi and lusvertikimab, the cornerstone assets of our 2026–2028 roadmap. In parallel, the Company continues to actively assess financing options to fully support the progression of its late‑stage clinical portfolio."

OSE‑230: Strategic Focus on Near‑Term Value

OSE Immunotherapeutics has decided to pause OSE‑230 as part of its ongoing portfolio prioritization and disciplined capital allocation strategy. This decision, following an amendment to the collaboration agreement with the development partner in December 2025, reflects the Company’s focus on advancing its most mature clinical programs and near‑term value drivers. OSE Immunotherapeutics will continue to assess opportunities to maximize value across its broader pipeline.

BI 770371: Partner‑Led Realignment, Focus on Oncology

Although BI 770371 was well tolerated with a manageable safety profile, Boehringer Ingelheim has decided to discontinue development of BI 770371 for people with liver cirrhosis caused by MASH after an exploratory Phase 2 study (NCT06675929) did not demonstrate efficacy to support further development in this indication.

This MASH decision does not impact BI 770371’s ongoing oncology development, which was the initial and lead program of the OSE and Boehringer Ingelheim collaboration, where the mechanism of action is distinct and multiple Phase 1 programs remain active and progressing as planned.

Additional Pipeline Prioritization

As part of the Company’s ongoing portfolio streamlining, OSE will also discontinue exploratory research activities related to the CLEC‑1 programme in oncology, an early myeloid checkpoint target still at preclinical stage. While scientifically promising, CLEC‑1 in oncology does not fall within the Company’s immediate clinical or partnership priorities. This decision further aligns OSE’s portfolio with its late‑stage value creation strategy.

Expected Value Inflection Points over OSE’s three-year strategic plan (2026-2028)

On January 29, 20261, OSE announced the selection of chronic pouchitis and hidradenitis suppurativa (HS) as the next potential targeted indications for lusvertikimab (OSE‑127), based on strong IL‑7R‑driven biological rationale. In parallel, the Company is developing a subcutaneous formulation to advance lusvertikimab in ulcerative colitis (UC) and completing the Tedopi Phase 3 in NSCLC.

This 2026-2028 strategic plan comes with significant expected value inflection points, including2:

Q2 2026: Tedopi Ovarian Cancer Investigator Sponsored Trial Phase 2 read-out
Q3 2026: Tedopi NSCLC Pivotal Phase 3 interim futility analysis
H2 2026: Tedopi 2L NSCLC combo Investigator Sponsored Trial Phase 2 read-out
H1 2027: Lusvertikimab sub-cutaneous formulation readiness
H2 2027: Possible start of Ulcerative Colitis Phase 2b/3
Q1 2028: Tedopi NSCLC Pivotal Phase 3 read-out
2028: Lusvertikimab 1st Phase 2 read-out in pouchitis or hidradenitis suppurativa.

(Press release, OSE Immunotherapeutics, MAR 2, 2026, View Source [SID1234663199])

On March 2, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar will deliver an investor presentation and corporate update. The presentation will include a review of recent clinical milestones across the Company’s oncology pipeline, including:

Encouraging survival observations and regulatory approval for substantial dose escalation in the Company’s ongoing Phase 1 ovarian cancer CAR-T trial; and
Final Phase 1 data from the breast cancer vaccine program, which met primary endpoints and demonstrated favorable tolerability and protocol-defined immune responses in the majority of participants.
The presentation will be followed by a live question-and-answer session.

The Meeting may be accessed online at: www.virtualshareholdermeeting.com/ANIX2026

(Press release, Anixa Biosciences, MAR 2, 2026, View Source [SID1234663168])